New trial aims to snuff out hidden leukemia before it returns
NCT ID NCT06664879
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participants are enrolled so far, making this a very small and early study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MBG-453 and azacitidine
- What this could lead to
- If successful, this could point toward a way to prevent AML relapse by treating early signs of remaining cancer.
- What could go wrong
- This is a very early trial with only 3 participants, so results may not apply broadly. The drugs may cause side effects or fail to stop the cancer from returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse
- Supercharged donor cells aim to stop leukemia return after transplant